希俄斯乳香治疗控制良好的高血压：HYPER-MASTIC随机对照试验的结果。
完整摘要 · 中文译文
即便在血压控制良好的高血压患者中，残余心血管风险依然存在，部分由炎症、氧化应激和内皮功能障碍所致。希俄斯乳香（Pistacia lentiscus var. Chia）在实验和临床环境中均显示出降压、抗氧化和血管效应。本试验评估了在血压控制良好的高血压个体中补充希俄斯乳香是否能带来额外的心血管获益。在这项双盲、随机、安慰剂对照试验中，106名基于SCORE2评分、患有稳定且控制良好的高血压并具有不同心血管风险水平的成年人，接受了低剂量希俄斯乳香（1500毫克/天）、高剂量希俄斯乳香（2800毫克/天）或安慰剂治疗3个月。主要终点是24小时动态收缩压和舒张压的变化。次要终点包括血管功能、外周血单个核细胞和红细胞中的氧化应激及蛋白酶体活性。在预设的高风险亚组中进行了转录组学分析。希俄斯乳香补充剂耐受性良好，高依从性通过血浆中乳香二烯酮酸和异乳香二烯酮酸的剂量依赖性升高得到证实。干预后，24小时收缩压或舒张压未观察到显著的组间差异。各组的氧化应激标志物和蛋白酶体活性保持不变。在高风险参与者中，乳香补充剂诱导了明显的转录组学变化，尤其是在与内皮连接组织和血管完整性相关的通路中。总体而言，在血压已得到良好控制的高血压患者中，为期3个月的希俄斯乳香补充剂未改变动态血压或全身氧化应激/蛋白酶体标志物，但在高风险个体中引起了与血管保护相关的转录组学变化。 总体而言，在血压控制良好且基线心血管风险较低的成人中，奇奥斯乳香补充剂在3个月内未降低血压，这可能反映了天花板效应。转录组学发现提示，在残余心血管风险较高的个体中存在具有生物学意义的血管效应，支持未来在高风险人群中进行研究。
完整摘要 · 英文原文
Residual cardiovascular risk persists in patients with adequately controlled hypertension, driven partly by inflammation, oxidative stress and endothelial dysfunction. Chios mastic (Pistacia lentiscus var. Chia) has shown antihypertensive, antioxidant and vascular effects in experimental and clinical settings. This trial evaluated whether Chios mastic supplementation confers additional cardiovascular benefits in well-controlled hypertensive individuals. In this double-blind, randomized, placebo-controlled trial, 106 adults with stable, well-controlled hypertension and variable cardiovascular risk, based on SCORE2, received low-dose Chios mastic (1500 mg/day), high-dose Chios mastic (2800 mg/day) or placebo for 3 months. Primary endpoints were changes in 24-h ambulatory systolic and diastolic blood pressure. Secondary endpoints included vascular function, oxidative stress and proteasome activity in peripheral blood mononuclear cells and red blood cells. Transcriptomic profiling was performed in a predefined high-risk subgroup. Chios mastic supplementation was well tolerated, with high adherence confirmed by dose-dependent increases in plasma masticadienonic and isomasticadienonic acids. No significant between-group differences were observed in 24-h systolic or diastolic blood pressure after the intervention. Oxidative stress markers and proteasome activity remained unchanged across groups. In high-risk participants, mastic supplementation induced distinct transcriptomic changes, particularly in pathways related to endothelial junction organization and vascular integrity. Overall, in adults with well-controlled hypertension and low baseline cardiovascular risk, Chios mastic supplementation did not lower blood pressure over 3 months, likely reflecting a ceiling effect. Transcriptomic findings suggest biologically meaningful vascular effects in individuals with higher residual cardiovascular risk, supporting future investigation in higher-risk populations.